A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : hERG / human ether-a-go-go-related gene

[Related PubMed/MEDLINE]
Total Number of Papers: 992
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   hERG  (>> Co-occurring Abbreviation)
Long Form:   human ether-a-go-go-related gene
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo. ---
2022 BayeshERG: a robust, reliable and interpretable deep learning model for predicting hERG channel blockers. ---
2022 Biphenyl scaffold for the design of NMDA-receptor negative modulators: molecular modeling, synthesis, and biological activity. NAM, NMDA
2022 Cardiac Electropharmacological Effects of Antidiarrheal Drug Loperamide and Its Antidote Naloxone in Anesthetized Guinea Pigs. ECG, MAP
2022 Cell-Based hERG Channel Inhibition Assay in High-Throughput Format. ---
2022 Design, synthesis and biological activity evaluation of a series of bardoxolone methyl prodrugs. CTSB, CUK, DN, PEG
2022 Discovery of 2-vinyl-10H-phenothiazine derivatives as a class of ferroptosis inhibitors with minimal human Ether-a-go-go related gene (hERG) activity for the treatment of DOX-induced cardiomyopathy. SAR
2022 Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity. FGFR3
2022 Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. hiPSC-CMs, SGK1
10  2022 Establishment of human embryonic stem cell WAe009-A-74 carrying a Long QT syndrome mutation in KCNH2. LQT2
11  2022 HergSPred: Accurate Classification of hERG Blockers/Nonblockers with Machine-Learning Models. LQTS
12  2022 High-Throughput Chemical Screening and Structure-Based Models to Predict hERG Inhibition. CV, NCATS, qHTS
13  2022 Identification and New Indication of Melanin-Concentrating Hormone Receptor 1 (MCHR1) Antagonist Derived from Machine Learning and Transcriptome-Based Drug Repositioning Approaches. LDLR, MCHR1, NASH
14  2022 Identification of novel bioactive compounds from Olea europaea by evaluation of chemical compounds in the OliveNet™ library: in silico bioactivity and molecular modelling, and in vitro validation of hERG activity. P-gp, SMD
15  2022 In-situ and amplification-free imaging of hERG ion channels at single-cell level using a unique core-molecule-shell-secondary antibody SERS nanoprobe. SERS
16  2022 Inhibition of human ether-à-go-go-related gene K+ currents expressed in HEK293 cells by three gingerol components from ginger. ---
17  2022 Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent. CNS, IND
18  2022 Ion channel model reduction using manifold boundaries. MBAM
19  2022 Lead optimization of pyrido[2,3-d][1]benzazepin-6-one derivatives leading to the discovery of a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) antagonist (DS69910557). hPTHR1
20  2022 Ligand-based prediction of hERG-mediated cardiotoxicity based on the integration of different machine learning techniques. SMOTE
21  2022 Loperamide-Induced Torsades de Pointes. ---
22  2022 Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome. diLQTS, TdP
23  2022 Molecular determinants for the high-affinity blockade of hERG K+ channel by tolterodine. ---
24  2022 Mutagenicity and safety pharmacology of a standardized antidiabetic polyherbal formulation. DRF, FOB, MN
25  2022 Pharmacological characterisation of electrocardiogram J-Tpeak interval in conscious Guinea pigs. QT, TdP
26  2022 Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy. Ang II, PCH
27  2022 Pore opening, not voltage sensor movement, underpins the voltage-dependence of facilitation by a hERG blocker. ---
28  2022 Predicting hERG channel blockers with directed message passing neural networks. D-MPNN
29  2022 Repurposing drugs as COVID-19 therapies: A toxicity evaluation. CPE, PLD, SARS-CoV-2
30  2022 Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics. ---
31  2022 The grapefruit polyphenol naringenin inhibits multiple cardiac ion channels. AP, CiPA, ECG
32  2022 The Linkage Phase of the Polymorphism KCNH2-K897T Influences the Electrophysiological Phenotype in hiPSC Models of LQT2. hiPSC-CMs, hiPSCs, LQT2, SNP
33  2022 Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K+ Channel. ---
34  2022 Vicious LQT induced by a combination of factors different from hERG inhibition. APD, EADs, ECG, LQT, TdP, VF
35  2021 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system. ECG, LVDP, NPSs, PAK1
36  2021 A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity. ---
37  2021 Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers. CI, QTcF
38  2021 Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome. AD, LQTS, TdP
39  2021 Association between the serum concentrations and mutational status of IL-8, IL-27 and VEGF and the expression levels of the hERG potassium channel gene in patients with colorectal cancer. CRC
40  2021 Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. AMPK, mTOR, PCSK9
41  2021 Cardiotoxicity assessment using 3D vascularized cardiac tissue consisting of human iPSC-derived cardiomyocytes and fibroblasts. ADD, hiPSC-CMs, MCS
42  2021 Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. FQs, HCQ, SAES-CoV-2
43  2021 COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. LQTS
44  2021 Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. KRAS, MAPK, NF-1, PK, RTK, SH2
45  2021 Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect. DA
46  2021 Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives. GPR119
47  2021 Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach. HBA
48  2021 Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. EZH2, SAR
49  2021 Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. MIC
50  2021 Disruption of protein quality control of the human ether-à-go-go related gene K+ channel results in profound long QT syndrome. hiPSC-CMs, LQTS, RNF207
51  2021 Dual Mechanisms of Cardiac Action Potential Prolongation by 4-Oxo-Nonenal Increasing the Risk of Arrhythmia; Late Na+ Current Induction and hERG K+ Channel Inhibition. 4-HNE, 4-ONE, APD, INaL
52  2021 Flavonoids and hERG channels: Friends or foes? ---
53  2021 Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation. ECG, hiPSC-CMs, MAP
54  2021 hERG-deficient human embryonic stem cell-derived cardiomyocytes for modelling QT prolongation. CM, hESC, LQT2, MEA
55  2021 Induced Pluripotent Stem Cell-Derived Cardiomyocytes with SCN5A R1623Q Mutation Associated with Severe Long QT Syndrome in Fetuses and Neonates Recapitulates Pathophysiological Phenotypes. CM, EAD, iPSC, LQT3
56  2021 Investigation of PAS and CNBH domain interactions in hERG channels and effects of long-QT syndrome-causing mutations with surface plasmon resonance. CNBH, LQTS, PAS, SPR
57  2021 L51P, a novel mutation in the PAS domain of hERG channel, confers long QT syndrome by impairing channel activation. LQTS, MD, PAS, PME
58  2021 Mechanisms of gefitinib-induced QT prolongation. APD, NSCLC
59  2021 Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity. NCEs
60  2021 Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. ALK2, BMP
61  2021 Parallel Recordings of Transmembrane hERG Channel Currents Based on Solvent-Free Lipid Bilayer Microarray. BLMs, Si
62  2021 Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. COVID-19, SARS-CoV-2
63  2021 Pharmacological corrections of the mutant hERG channels by posaconazole. HEK, WT
64  2021 Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis. 5-HT, AEs
65  2021 Proarrhythmic effects induced by benzethonium chloride and domiphen bromide in vitro and in vivo. BZT, DMP, hiPSC-CMs
66  2021 Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity. ---
67  2021 Refinement of a cryo-EM structure of hERG: Bridging structure and function. MDFF, VSD
68  2021 Role and mechanism of chaperones calreticulin and ERP57 in restoring trafficking to mutant HERG‑A561V protein. CNX, CRT, ERP57, WT
69  2021 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. CNS
70  2021 Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth. TB
71  2021 Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study. IFs, SVM
72  2021 The Effect of a Synthetic Estrogen, Ethinylestradiol, on the hERG Block by E-4031. ---
73  2021 TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction. RMSE, rs, SVR
74  2020 AKAP5 anchors PKA to enhance regulation of the HERG channel. AKAPs, beta-AR, LQTS, PKA
75  2020 Assessment of spatial heterogeneity of ventricular repolarization after multi-channel blocker drugs in healthy subjects. SHVR
76  2020 Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. hAMCase
77  2020 Critical Assessment of Artificial Intelligence Methods for Prediction of hERG Channel Inhibition in the "Big Data" Era. AI, DNNs, RNNs
78  2020 Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development. ---
79  2020 DeepHIT: a deep learning framework for prediction of hERG-induced cardiotoxicity. NPV, UT
80  2020 Discovery of a Novel Class of State-Dependent NaV1.7 Inhibitors for the Treatment of Neuropathic Pain. CNS, NaV
81  2020 Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. HDAC, MDR
82  2020 Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines. ---
83  2020 Fentanyl-Induced Block of hERG Channels Is Exacerbated by Hypoxia, Hypokalemia, Alkalosis, and the Presence of hERG1b. ---
84  2020 Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. BIM I, PLGA
85  2020 G604S-HERG mutation in LQT2 leads to autophagy via the UPR-related pathway. ER, ERS, LQTS, UPR
86  2020 HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential. ---
87  2020 hERG toxicity assessment: Useful guidelines for drug design. EMA, FDA
88  2020 hERG-Att: Self-attention-based deep neural network for predicting hERG blockers. ---
89  2020 In vitro and in vivo cardiac toxicity of flavored electronic nicotine delivery systems. ENDS
90  2020 In-vitro safety and off-target profile of the anti-parasitic arylmethylaminosteroid 1o. HDAC, PDE, sc1o, TEER
91  2020 Inhibition of Human Ether-A-Go-Go-Related Gene (hERG) Potassium Current by the Novel Sotalol Analogue, Soestalol. ---
92  2020 Inhibitory effects of four active components in saffron on human ether-a-go-go-related gene (hERG) K+ currents. ---
93  2020 Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative. CiPA, ICH, TdP
94  2020 Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment. ---
95  2020 Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. GBM
96  2020 Neurological Disorders and Risk of Arrhythmia. ANS, HPA, PTSD
97  2020 Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced hERG Inhibitory Activity. AMPK
98  2020 Prediction of hERG potassium channel blockage using ensemble learning methods and molecular fingerprints. AUC
99  2020 Serine mutation of a conserved threonine in the hERG K+ channel S6-pore region leads to loss-of-function through trafficking impairment. WT
100  2020 Structure-Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. ETR, HIV-1, NNRTI